General Updates

2 July 2026 To To The Secretary, The Manager, Listing Department, Listing Department, BSE Limited, The National Stock Exchange of India Ltd, 1st Floor, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Mumbai 400001. Bandra (East), Mumbai 400051. Scrip Code: 540975 Scrip Symbol: ASTERDM Dear Sir / Madam, Subject: Updated outcome of the Meeting of the Board of Directors held on Wednesday, 1 July 2026 Ref: E-mail received from BSE on 02 July 2026 requesting submission of fresh corporate Announcement seeking addition details for the announcement made by the Company In response to the e-mail received from BSE on 2 July 2026 seeking additional details w.r.t. the names of listed entities in which the resigning Independent Director(s) holds directorships, the Company hereby submits the updated outcome of the Board Meeting held on 1 July 2026 after incorporating the aforesaid details, as set out in Annexure A. The stock exchange and stakeholders are requested to take the same on record. Thank you. Yours faithfully, For Aster DM Healthcare Limited Hemish Purushottam Company Secretary and Compliance Officer M. No. A24331 Annexure – A 1 July 2026 (updated as on date) To To The Secretary, The Manager, Listing Department, Listing Department, BSE Limited, The National Stock Exchange of India Ltd, 1st Floor, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Mumbai 400001. Bandra (East), Mumbai 400051. Scrip Code: 540975 Scrip Symbol: ASTERDM Dear Sir / Madam, Subject: Outcome of the Meeting of the Board of Directors held on Wednesday, 1 July 2026 Ref: Regulation 30 read-with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) With reference to the subject captioned, the Board Directors of the Aster DM Quality Care Limited, subject to receipt of fresh certificate of incorporation (currently Aster DM Healthcare Limited), at its meeting held on Wednesday, 1 July 2026, inter alia: A. CHANGE IN BOARD OF DIRECTORS: Upon recommendation of the Nomination & Remuneration Committee (“NRC”), subject to approval of the shareholders of the Company, the Board approved the following appointments of Directors with effect from 1 July 2026, pursuant to the implementation of the Scheme of Amalgamation and consequent changes in the organizational structure and management framework of the merged entity: i. Appointment of Mr. Varun Khanna (DIN:03584124) as an Additional Director, Designated as Managing Director & Group Chief Executive Officer (Key Managerial Personnel) of the Company for a term of five (5) years. ii. Appointment of Mr. Neeraj Jain (DIN: 00348591), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. iii. Appointment of Mr. Kewal Handa (DIN: 00056826), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. iv. Appointment of Mr. V K Mathews (DIN: 00049414), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. v. Appointment of Ms. Ayshwarya Vikram (DIN: 08153649) as an Additional Director, designated as Non- Executive Director of the Company vi. Appointment of Mr. Ganesh Mani (DIN: 08385423) as an Additional Director, designated as Non- Executive Director of the Company. The above appointees have affirmed that they are not debarred from holding the office of director by virtue of any order of the Securities and Exchange Board of India or any other such authority. B. RESIGNATION OF DIRECTORS i. Resignation of Mr. Maniedath Madhavan Nambiar (DIN: 01122411) and Mr. C. J. George (DIN: 00003132), as Independent Directors of the Company with effect from 1 July 2026. ii. Resignation of Dr. Zeba Azad Moopen (DIN: 03604401) and Mr. Shamsudheen Bin Mohideen Mammu Haji (DIN: 02007279) as Non-Executive Directors of the Company with effect from 1 July 2026. The above Directors have confirmed that there are no other material reasons for the resignation other than those mentioned in their respective resignation letters. The Details as required under the SEBI Master Circular dated 30 January 2026, with regard to appointment and resignation of Directors are provided as Annexure I and copy of the resignation letters of the Directors is enclosed as Annexure II with this letter. C. CHANGES IN COMMITTEE COMPOSITIONS Consequent to the above change in Directors, the Board re-constituted its Committees w.e.f. 01 July 2026. The revised composition of the Committees is enclosed as Annexure III to this letter. D. CHANGES IN THE SENIOR MANAGEMENT PERSONNEL (“SMP”) OF THE COMPANY ON ACCOUNT OF RESIGNATION The Board of Directors noted the resignation of Mr. Hitesh Dhaddha as Chief Investor Relations and M&A Officer with effect from close of business hours of 18 July 2026. The relevant details as required under the SEBI Master Circular dated 30 January 2026, are provided as Annexure IV and resignation letter of Ms. Hitesh Dhaddha are enclosed as Annexure V to this letter. ON ACCOUNT OF CHANGE IN ORGANISATIONAL STRUCTURE Consequent to the change in the organizational structure of the Company and pursuant to the Scheme, the Board of Directors approved the revised list of SMPs of the Company with effect from 1 July 2026, in terms of Regulation 16(1)(d) of the SEBI Listing Regulations, as follows: Sl. No. Name of the SMP Designation Nature of change 1 Mr. Ramesh Kumar S Chief Executive Officer (India I) Change in Designation 2 Dr. Pawan Kumar Chief Executive Officer (India II) Appointment 3 Mr. Vishal Maheshwari Chief Executive Officer (India III) Appointment 4 Dr. Ratnadeep Chaskar Chief Executive Officer (Bangladesh) Appointment 5 Mr. Vinod Raman Chief Digital Officer Appointment 6 Mr. S V Kiran Group Chief People Officer Appointment 7 Ms. Richa Singh Group Legal Officer Appointment 8 Mr. Sunil Kumar M R Group Chief Financial Officer * Change in Designation Sl. No. Name of the SMP Designation Nature of change 9 Mr. Sudeep Dey Chief Information Officer Change in Designation 10 Dr. Somashekhar S P Group Medical Officer Change in Designation 11 Mr. Durga Prasanna Nayak Head of Human Resources Cessation 12 Mr. Hemakumar Nemmali Country Head – Supply Chain Management Cessation 13 Dr. Nalanda Jayadev Chief Executive Officer, Aster Medcity Kochi Cessation & Senior Consultant - Forensic Medicine 14 Mr. Vineesh Kumar Ghei Regional Country Head Sales Cessation 15 Mr. Hemish Purushottam Company Secretary and Compliance Officer No Change 16 Mr. Hari Prasad V K Chief Internal Audit and Risk Management No Change Officer *Mr. Sunil Kumar M R shall assume the additional role of Head – Investor Relations w.e.f. 19 July 2026. The relevant details as required under the SEBI Master Circular dated 30 January 2026, are provided as Annexure IV to this letter. E. AMENDMENT TO ASTER DM HEALTHCARE LIMITED EMPLOYEE STOCK OPTION SCHEME 2026 Based on the recommendation of the Nomination and Remuneration Committee (“NRC”) vide its meeting held on July 1, 2026, and subject to the approval of the shareholders of the Company, the Board approved the amendments to the Aster DM Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP Scheme 2026”), which was previously considered and approved by the NRC and the Board at their respective meetings held on 29 January 2026 and 30 January 2026, details of which are specified below: a. Updated the name of the ESOP Scheme 2026 to ‘Aster DM Quality Care Limited Employee Stock Option Scheme 2026’. b. The effective date of the ESOP Scheme 2026 has been updated to be the date on which the shareholders of the Company approve it. c. Grants under the ESOP Scheme 2026 (upon approval by the shareholders) are to be made to the eligible employees of the Company and its unlisted subsidiaries. d. Removal of provisions on re-pricing of options under the ESOP Scheme 2026. Please refer to the detailed disclosure set out in Annexure-VI to this letter [Showing first 8,000 characters — download PDF for full document]